Skip to main content
Kisqali patient portrayal.

What do the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) say about KISQALI in HR+/HER2- early (stage II/III at high risk of recurrence) and metastatic breast cancer?

NCCN Category 1 preferred

National Comprehensive Cancer Network® (NCCN®) differentiates ribociclib (KISQALI®) as the first and only Category 1 Preferred treatment option when used in combination with an AI for appropriate patients with HR+/HER2- mBC in 1L and for appropriate patients with HR+/HER2- eBC, including those with high-risk node-negative disease.1

 
In HR+/HER2- eBC, high-risk node-negative disease is defined as either tumor size >5 cm, or if tumor size 2-5 cm, either grade 2 (with high genomic risk or Ki-67 ≥20%), or grade 3.1
There is controversy on the choice of CDK4/6 inhibitor as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.1
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.1
Category 1: Based upon high-level evidence (≥1 randomized phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.1
1L, first line; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.

Take a closer look at what the NCCN Guidelines® for Breast Cancer say about KISQALI: Download the clinical flashcard

MORE oncologists’ top choice

#1 Prescribed

KISQALI is the most prescribed CDK4/6 inhibitor across both HR+/HER2- eBC & mBC

June 2026 IQVIA custom breast cancer market sizing report.

See what KISQALI could mean for the patients in your practice


Get additional information and resources on the NCCN Guidelines for ribociclib (KISQALI) and KISQALI access

 

NCCN clinical flashcard

Clinical Flashcard: NCCN Guidelines for KISQALI

Review the NCCN Guidelines for KISQALI in greater detail.
Download
KISQALI access support guide

KISQALI Access Support Guide

A guide to support patients during the insurance coverage process for KISQALI.
Download
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.6.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 30, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Data on file. CDK TRx and NBRx share data from IQVIA market sizing report. Novartis Pharmaceuticals Corp; 2026.